The DOI matches its Crossref record; 136 of the 138 references it cites were found in a registry or an index, and 2 are not checked yet.
Liver fibrosis
Open accessAbstract
Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation. Our knowledge of the cellular and molecular mechanisms of liver fibrosis has greatly advanced. Activated hepatic stellate cells, portal fibroblasts, and myofibroblasts of bone marrow origin have been identified as major collagen-producing cells in the injured liver. These cells are activated by fibrogenic cytokines such as TGF-beta1, angiotensin II, and leptin. Reversibility of advanced liver fibrosis in patients has been recently documented, which has stimulated researchers to develop antifibrotic drugs. Emerging antifibrotic therapies are aimed at inhibiting the accumulation of fibrogenic cells and/or preventing the deposition of extracellular matrix proteins. Although many therapeutic interventions are effective in experimental models of liver fibrosis, their efficacy and safety in humans is unknown. This review summarizes recent progress in the study of the pathogenesis and diagnosis of liver fibrosis and discusses current antifibrotic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The current study amends this fibrocentric concept by demonstrating fibrosis-independent roles for HSCs through RSPO3, regulating critical parameters that affect CLD progression and outcomes, including metabolic hepatocyte functions, liver regeneration and hepatocyte death2,49,50.”
From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [2]
In the citing paper
“In more advanced disease stages, the ECM can replace functional liver parenchyma and thereby contribute to the development of liver cirrhosis, which is characterized by bridging fibrosis, regenerative nodules, and the loss of liver function [230].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · cites this paper as [230]
In the citing paper
“Two of the prototype cytokines responsible for the activation of HSCs during liver injury are the transforming growth factor-β (TGF-β) and the platelet-derived growth factor (PDGF).[3]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
The Versatile Role of microRNA-30a in Human Cancer
Wang, C., Yang, X., Chen, Y., & Chen, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471111 · Cited by 3,414
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Thomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci20530 · Cited by 2,715
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,171
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
Regev, A., Berho, M. E., Jeffers, L. J., Milikowski, C., Molina, E. G., Pyrsopoulos, N., Feng, Z.-Z., Reddy, K. R., & Schiff, E. R. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.06038.x · Cited by 2,078
Xu, D., He, X., Chang, Y., Sun, S., Xu, C., & Lin, J. (2012) · Hepatogastroenterology · doi:10.5754/hge12458 · Cited by 1,977
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Flagged first, then by citations
Research works printed but not linked: 9
- Soyer, 1976, Surgery., 79, 601
- Otto, 1980, Adv. Exp. Med. Biol., 132, 509
- Wasser, 1999, Ann. Acad. Med. Singapore., 28, 109
- Brunt, 2004, Semin. Liver Dis., 24, 3
- Phillips, 2004, J. Clin. Invest., 114, 438, 10.1172/jci200420997 · DOI
- Kmiec, 2001, Adv. Anat. Embryol. Cell Biol., 161, III–XIII, 1–151
- Thurman, 1998, Am. J. Physiol., 275, G605
- Wei, 2000, World J. Gastroenterol., 6, 540
- Tuncer, 2003, Exp. Toxicol. Pathol., 55, 159
Cited by
Sorted by citations
Items 301–400 of 1,040
Jung, Y., Brown, K. D., Witek, R. P., Omenetti, A., Yang, L., Vandongen, M., Milton, R. J., Hines, I. N., Rippe, R. A., Spahr, L., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.022 · Cited by 171
Engineering 3D Hydrogels for Personalized In Vitro Human Tissue Models
Liaw, C., Ji, S., & Güvendiren, M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701165 · Cited by 171
Nonalcoholic Fatty Liver Disease as a Complication of Insulin Resistance
Abdelmalek, M. F., & Diehl, A. M. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.06.001 · Cited by 170
Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies
Li, J., Liao, Z., Ping, J., Xu, D., & Wang, H. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2180-y · Cited by 169
Anti-fibrogenic strategies and the regression of fibrosis
Kisseleva, T., & Brenner, D. A. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.02.011 · Cited by 169
Self-citationCrossan, C., Tsochatzis, E. A., Longworth, L., Gurusamy, K. S., Davidson, B. R., Rodríguez‐Perálvarez, M., Mantzoukis, K., O’Brien, J., Thalassinos, E., Papastergiou, V., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19090 · Cited by 169
Niuchangchih (Antrodia camphorata) and its potential in treating liver diseases
Ao, Z.-H., Xu, Z., Lu, Z., Xu, H.-Y., Zhang, X.-M., & Dou, W. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.10.039 · Cited by 169
Matrix metalloproteinase functions in hepatic injury and fibrosis
Roderfeld, M. (2017) · Matrix Biology · doi:10.1016/j.matbio.2017.11.011 · Cited by 168
Novo, E., Marra, F., Zamara, E., di Bonzo, L. V., Monitillo, L., Cannito, S., Petrai, I., Mazzocca, A., Bonacchi, A., Franco, R. S. M. D., et al. (2006) · Gut · doi:10.1136/gut.2005.082701 · Cited by 168
The spleen in liver cirrhosis: revisiting an old enemy with novel targets
Li, L., Duan, M., Chen, W., Jiang, A., Li, X., Yang, J. J., & Li, Z. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1214-8 · Cited by 167
Hyaluronan synthase 2–mediated hyaluronan production mediates Notch1 activation and liver fibrosis
Yang, Y. M., Noureddin, M., Liu, C., Ohashi, K., Kim, S. Y., Ramnath, D., Powell, E. E., Sweet, M. J., Roh, Y. S., Hsin, I.-F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat9284 · Cited by 166
Natural killer and natural killer T cells in liver fibrosis
Gao, B., & Radaeva, S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.09.008 · Cited by 165
Chen, C., Chen, J., Wang, Y., Fang, L., Guo, C., Sang, T., Peng, H., Zhao, Q., Chen, S., Lin, X., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154626 · Cited by 165
Pathophysiology of Liver Fibrosis
Pinzani, M. (2015) · Digestive Diseases · doi:10.1159/000374096 · Cited by 164
Minicis, S. D., & Brenner, D. A. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.04.016 · Cited by 163
Self-citationCasas‐Grajales, S. (2015) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v6.i3.59 · Cited by 163
Reversal of liver cirrhosis: current evidence and expectations
Jung, Y. K., & Yim, H. J. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.268 · Cited by 163
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review
Wang, M., Ma, L., Yang, Y., Xiao, Z., & Wan, J. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1544542 · Cited by 163
Cao, S., Yaqoob, U., Das, A., Shergill, U., Jagavelu, K., Huebert, R. C., Routray, C., Abdelmoneim, S. S., Vasdev, M. M., Leof, E. B., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41203 · Cited by 163
3D in vitro models of liver fibrosis
van Grunsven, L. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.004 · Cited by 162
Wang, R., Song, F., Li, S., Wu, B., Gu, Y., & Yuan, Y. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s194787 · Cited by 162
Schelbert, K. B. (2009) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2009.01.009 · Cited by 161
Lim, J., Oh, M., Kim, W., Sohn, H., & Park, S. I. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22824 · Cited by 161
The role of mouse strain differences in the susceptibility to fibrosis: a systematic review
Walkin, L., Herrick, S. E., Summers, A., Brenchley, P. E., Hoff, C. M., Korstanje, R., & Margetts, P. J. (2013) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-6-18 · Cited by 160
Hepatocyte nuclear factor 4α attenuates hepatic fibrosis in rats
Yue, H.-Y., Yin, C., Jl, H., Zeng, X. Y., Chen, Y., Zhong, W. H., Hu, P.-F., Deng, X., Tan, Y.-X., Zhang, J.-P., et al. (2009) · Gut · doi:10.1136/gut.2008.174904 · Cited by 160
HCV Induces Oxidative and ER Stress, and Sensitizes Infected Cells to Apoptosis in SCID/Alb-uPA Mice
Joyce, M., Walters, K., Lamb, S.-E., Yeh, M. M., Zhu, L.-F., Kneteman, N. M., Doyle, J. S. G., Katze, M. G., & Tyrrell, D. L. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000291 · Cited by 159
Fibrosis: a key feature of Fabry disease with potential therapeutic implications
Weidemann, F., Sánchez-Niño, M. D., Politei, J. M., Oliveira, J. P., Wanner, C., Warnock, D. G., & Ortíz, A. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-116 · Cited by 159
S100A4 promotes liver fibrosis via activation of hepatic stellate cells
Chen, L., Li, J., Zhang, J., Dai, C., Liu, X., Wang, J., Gao, Z., Guo, H., Wang, R., Lu, S., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.035 · Cited by 158
Adachi, M., Osawa, Y., Uchinami, H., Kitamura, T., Accili, D., & Brenner, D. A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.033 · Cited by 158
Self-citationMejías, M., Gallego, J. G., Naranjo‐Suarez, S., Ramirez, M., Pell, N., Manzano, À., Suñer, C., Bartrons, R., Méndez, R., & Fernández, M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.008 · Cited by 158
Zhang, J., Li, Y., Liu, Q., Huang, Y., Li, R., Wu, T., Zhang, Z., Zhou, J., Huang, H., Tang, Q., et al. (2020) · Hepatology · doi:10.1002/hep.31418 · Cited by 158
Tissue mechanics in stem cell fate, development, and cancer
Hayward, M.-K., Muncie, J. M., & Weaver, V. M. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.05.011 · Cited by 159
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Iwaisako, K., Haimerl, M., Paik, Y.-H., Taura, K., Kodama, Y., Sirlin, C., Yu, E., Yu, R. T., Downes, M., Evans, R. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202464109 · Cited by 157
Self-citationMoreno, M., Chaves, F. J., Sancho‐Bru, P., Ramalho, F. S., Ramalho, L. N. Z., Mansego, M. L., Ivorra, C., Domínguez, M., Conde, L., Millán, C., et al. (2009) · Hepatology · doi:10.1002/hep.23421 · Cited by 157
Self-citationGlässner, A., Eisenhardt, M., Krämer, B., Körner, C., Coenen, M., Sauerbruch, T., Spengler, U., & Nattermann, J. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.54 · Cited by 157
Nakamura, T., Torimura, T., Sakamoto, M., Hashimoto, O., Taniguchi, E., Inoue, K., Sakata, R., Kumashiro, R., Murohara, T., Ueno, T., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.110 · Cited by 156
Heinrichs, D., Knauel, M., Offermanns, C., Berres, M., Nellen, A., Leng, L., Schmitz, P., Bucala, R., Trautwein, C., Weber, C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107023108 · Cited by 156
EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling
Park, S.-A., Kim, M.-J., Park, S.-Y., Kim, J.-S., Lee, S., Woo, H. A., Kim, D.-K., Nam, J., & Sheen, Y. Y. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1798-6 · Cited by 156
Liver Fibrogenesis: A New Role for the Renin–Angiotensin System
Bataller, R. A., Sancho‐Bru, P., Ginès, P., & Brenner, D. A. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.1346 · Cited by 155
Self-citationBárcena, C., Stefanović, M., Tutusaus, A., Joannas, L. D., Menéndez, A., García‐Ruiz, C., Sancho‐Bru, P., Marı́, M., Caballería, J., Rothlin, C. V., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.013 · Cited by 154
Dechêne, A., Sowa, J., Gieseler, R. K. H., Jochum, C., Bechmann, L. P., Fouly, A. E., Schlattjan, M., Saner, F. H., Baba, H. A., Paul, A., et al. (2010) · Hepatology · doi:10.1002/hep.23754 · Cited by 154
Emerging role of microRNAs in liver diseases
Bala, S., Marcos, M., & Szabó, G. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.5633 · Cited by 154
The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders
Gregorio, J. D., Robuffo, I., Spalletta, S., Giambuzzi, G., Iuliis, V. D., Toniato, E., Martinotti, S., Conti, P., & Flati, V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607483 · Cited by 155
Sphingosine kinase 1 promotes liver fibrosis by preventing miR‐19b‐3p‐mediated inhibition of CCR2
Lan, T., Li, C., Yang, G., Sun, Y., Zhuang, L., Ou, Y., Li, H., Wang, G., Kisseleva, T., Brenner, D., et al. (2018) · Hepatology · doi:10.1002/hep.29885 · Cited by 153
Self-citationDuan, J., Ruan, B., Yan, X., Liang, L., Song, P., Yang, Z., Liu, Y., Dou, K., Han, H., & Wang, L. (2018) · Hepatology · doi:10.1002/hep.29834 · Cited by 153
Extracellular matrix alterations in senescent cells and their significance in tissue homeostasis
Mavrogonatou, E., Pratsinis, H., Papadopoulou, A., Karamanos, N. K., & Kletsas, D. (2019) · Matrix Biology · doi:10.1016/j.matbio.2017.10.004 · Cited by 153
Resistin as an Intrahepatic Cytokine
Bertolani, C., Sancho‐Bru, P., Failli, P., Bataller, R. A., Aleffi, S., DeFranco, R., Mazzinghi, B., Romagnani, P., Milani, S., Ginès, P., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060081 · Cited by 153
Self-citationHepatic lipid metabolism and non-alcoholic fatty liver disease in aging
Gong, Z., Tas, E., Yakar, S., & Muzumdar, R. H. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.12.022 · Cited by 153
Chávez, E., Reyes‐Gordillo, K., Segovia, J., Shibayama, M., Tsutsumi, V., Vergara, P., Moreno, M. G., & Muriel, P. (2007) · Journal of Applied Toxicology · doi:10.1002/jat.1249 · Cited by 152
Perugorria, M. J., Latasa, M. U., Nicou, A., Cartagena‐Lirola, H., Castillo, J., Goñi, S., Vespasiani‐Gentilucci, U., Zagami, M. G., Lotersztajn, S., Prieto, J., et al. (2008) · Hepatology · doi:10.1002/hep.22437 · Cited by 151
The Endothelium as a Driver of Liver Fibrosis and Regeneration
Lafoz, E., Ruart, M., Anton, A., Oncins, A., & Hernández–Gea, V. (2020) · Cells · doi:10.3390/cells9040929 · Cited by 152
Rezvani, M., Español-Suñer, R., Malato, Y., Dumont, L., Grimm, A. A., Kienle, E., Bindman, J. G., Wiedtke, E., Hsu, B. Y., Naqvi, S. J., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.05.005 · Cited by 150
Trépo, E., Gustot, T., Degré, D., Lemmers, A., Verset, L., Demetter, P., Ouziel, R., Quertinmont, E., Vercruysse, V., Amininejad, L., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.01.028 · Cited by 149
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
Takeda, K., Kojima, Y., Ikejima, K., Harada, K., Yamashina, S., Okumura, K., Aoyama, T., Frese, S., Ikeda, H., Haynes, N. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802702105 · Cited by 148
Integration of Technologies for Hepatic Tissue Engineering
Nahmias, Y., Francois Berthiaume, B., & Yarmush, M. L. (2006) · Springer eBooks · doi:10.1007/10_029 · Cited by 148
Role of TLR9 in hepatic stellate cells and experimental liver fibrosis
Gäbele, E., Mühlbauer, M., Dorn, C., Weiß, T. S., Froh, M., Schnabl, B., Wiest, R., Schölmerich, J., Obermeier, F., & Hellerbrand, C. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.096 · Cited by 148
Multipotent stromal cells: One name, multiple identities
Soliman, H., Theret, M., Scott, W., Hill, L., Underhill, T. M., Hinz, B., & Rossi, F. M. V. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.09.001 · Cited by 147
Hepatic stellate cells—the pericytes in the liver
Hellerbrand, C. (2013) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-012-1209-5 · Cited by 146
Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment
Berenguer, M., & Schuppan, D. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.014 · Cited by 146
Toll-Like Receptor Signaling and Liver Fibrosis
Aoyama, T., Paik, Y., & Seki, E. (2010) · Gastroenterology Research and Practice · doi:10.1155/2010/192543 · Cited by 146
Norona, L. M., Nguyen, D. G., Gerber, D. A., Presnell, S. C., & LeCluyse, E. L. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw169 · Cited by 146
Aneni, E. C., Oni, E., Martin, S. S., Blaha, M. J., Agatston, A. S., Feldman, T., Veledar, E., Conceição, R., Carvalho, J. A. M., Santos, R. D., et al. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000532 · Cited by 146
Diabetes and Hepatitis C: A Two-Way Association
Hammerstad, S. S., Grock, S., Lee, H. J., Hasham, A., Sundaram, N. K., & Tomer, Y. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00134 · Cited by 145
Shin, W. G., Park, S. H., Jang, M. K., Hahn, T. H., Kim, J. B., Lee, M. S., Kim, D. J., Jun, S., & Park, C. K. (2007) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.10.011 · Cited by 145
Transforming growth factor-beta differentially regulates oval cell and hepatocyte proliferation
Nguyen, L., Furuya, M. H., Wolfraim, L. A., Nguyen, A. P., Holdren, M. S., Campbell, J. S., Knight, B., Yeoh, G. C., Fausto, N., & Parks, W. T. (2006) · Hepatology · doi:10.1002/hep.21466 · Cited by 145
Progression of fibrosis in advanced chronic hepatitis C
Goodman, Z. D., Becker, R. L., Pockros, P. J., & Afdhal, N. H. (2007) · Hepatology · doi:10.1002/hep.21595 · Cited by 145
Zhu, Q., Zou, L., Jagavelu, K., Simonetto, D. A., Huebert, R. C., Jiang, Z.-D., DuPont, H. L., & Shah, V. H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.11.013 · Cited by 144
Kong, L., Zhou, Y., Bu, H., Lv, T., Shi, Y., & Yang, J. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0412-1 · Cited by 143
Nanoparticles for the treatment of liver fibrosis
Surendran, S. P., Thomas, R. G., Moon, M. J., & Jeong, Y. Y. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s145951 · Cited by 145
Fan, W., Liu, T., Chen, W. L., Hammad, S., Longerich, T., Haußer, I., Fu, Y., Li, N., He, Y., Liu, C., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.07.036 · Cited by 146
Oh, C. J., Kim, J., Min, A.-K., Park, K., Harris, R. A., Kim, H.-J., & Lee, I. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.11.012 · Cited by 143
Macías-Rodríguez, R. U., Ilarraza-Lomelí, H., Ruiz-Margáin, A., Ponce-de-León-Rosales, S., Vargas-Vorácková, F., García-Flores, O., Torre, A., & Duarte-Rojo, A. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.38 · Cited by 142
Preisser, L., Miot, C., Guillou‐Guillemette, H. L., Beaumont, É., Foucher, E. D., Garo, E., Blanchard, S., Frémaux, I., Croué, A., Fouchard, I., et al. (2014) · Hepatology · doi:10.1002/hep.27328 · Cited by 142
Bone-Marrow-Derived Mesenchymal Stem Cells for Organ Repair
Li, M., & Ikehara, S. (2013) · Stem Cells International · doi:10.1155/2013/132642 · Cited by 142
Revision and update on clinical practice guideline for liver cirrhosis
Suk, K. T., Baik, S. K., Yoon, J., Cheong, J. Y., Paik, Y. H., Lee, C. H., Kim, Y. S., Lee, J. W., Kim, D. J., Cho, S. W., et al. (2012) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2012.18.1.1 · Cited by 142
Chen, L., Zhang, C., Chen, L., Wang, X., Xiang, B., Wu, X., Guo, Y., Mou, X., Yuan, L., Chen, B., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0265 · Cited by 142
Prevention of liver cirrhosis in rats by curcumin
Bruck, R., Ashkenazi, M., Weiss, S., Goldiner, I., Shapiro, H., Aeed, H., Genina, O., Helpern, Z., & Pines, M. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01453.x · Cited by 142
Noninvasive assessment of portal hypertension in patients with cirrhosis
Thabut, D., Moreau, R., & Lebrec, D. (2010) · Hepatology · doi:10.1002/hep.24129 · Cited by 141
Wermuth, P. J., & Jiménez, S. A. (2015) · Clinical and Translational Medicine · doi:10.1186/s40169-015-0047-4 · Cited by 141
Use of mesenchymal stem cells to treat liver fibrosis: Current situation and future prospects
Berardis, S., Sattwika, P. D., Najimi, M., & Sokal, E. M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i3.742 · Cited by 140
Regulation of wound healing and organ fibrosis by toll-like receptors
Huebener, P., & Schwabe, R. F. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.017 · Cited by 140
Sun, W., Chang, S., Tai, D., Tan, N., Xiao, G., Tang, H., & Yu, H. (2008) · Journal of Biomedical Optics · doi:10.1117/1.3041159 · Cited by 140
Oxidative stress in alcoholic liver disease: Role of NADPH oxidase complex
Minicis, S. D., & Brenner, D. A. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05277.x · Cited by 140
Self-citationPPARγ agonists prevent TGFβ1/Smad3-signaling in human hepatic stellate cells
Zhao, C., Chen, W., Yang, L., Chen, L., Stimpson, S. A., & Diehl, A. M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.09.069 · Cited by 139
miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis
Dongiovanni, P., Meroni, M., Longo, M., Fargion, S. R., & Fracanzani, A. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123966 · Cited by 139
Nishio, T., Hu, R., Koyama, Y., Liang, S., Rosenthal, S. B., Yamamoto, G., Karin, D., Baglieri, J., Ma, H., Xu, J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.012 · Cited by 139
Self-citationPathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?
Khanam, A., Saleeb, P. G., & Kottilil, S. (2021) · Cells · doi:10.3390/cells10051097 · Cited by 143
What Increases Outflow Resistance in Primary Open-angle Glaucoma?
Tamm, E. R., & Fuchshofer, R. (2007) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2007.08.002 · Cited by 139
Critical Role of Plasminogen Activator Inhibitor-1 in Cholestatic Liver Injury and Fibrosis
Bergheim, I., Guo, L., Davis, M. A., Duveau, I., & Arteel, G. E. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.095042 · Cited by 139
Krizhanovsky, V., Xue, W., Zender, L., Yon, M., Hernando, E., & Lowe, S. W. (2008) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2008.73.048 · Cited by 138
Small interfering RNA: Discovery, pharmacology and clinical development—An introductory review
Ranasinghe, P., Addison, M. L., Dear, J. W., & Webb, D. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.15972 · Cited by 138
Thrombocytopenia Exacerbates Cholestasis-Induced Liver Fibrosis in Mice
Kodama, T., Takehara, T., Hikita, H., Shimizu, S., Li, W., Miyagi, T., Hosui, A., Tatsumi, T., Ishida, H., Tadokoro, S., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.054 · Cited by 138
The Influence of Sex Hormones in Liver Function and Disease
Kasarinaite, A., Sinton, M. C., Saunders, P. T. K., & Hay, D. C. (2023) · Cells · doi:10.3390/cells12121604 · Cited by 139
Hyun, J., Wang, S., Kim, J., Kim, G. J., & Jung, Y. (2015) · Scientific Reports · doi:10.1038/srep14135 · Cited by 137
The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis
Karin, D., Koyama, Y., Brenner, D. A., & Kisseleva, T. (2016) · Differentiation · doi:10.1016/j.diff.2016.07.001 · Cited by 138
Self-citationCross-species metabolomic analysis identifies uridine as a potent regeneration promoting factor
Liu, Z., Li, W., Geng, L., Sun, L., Wang, Q., Yu, Y., Yan, P., Liang, C., Ren, J., Song, M., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00361-3 · Cited by 137
Toll-like receptors, wound healing, and carcinogenesis
Kluwe, J., Mencin, A. M., & Schwabe, R. F. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0426-z · Cited by 137
Chemokine-directed immune cell infiltration in acute and chronic liver disease
Karlmark, K. R., Wasmuth, H. E., Trautwein, C., & Tacke, F. (2008) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2.2.233 · Cited by 137
Pascoli, M. D., Diví, M., Rodrı́guez-Vilarrupla, A., Rosado, E., Gracia‐Sancho, J., Vilaseca, M., Bosch, J., & García‐Pagán, J. C. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.012 · Cited by 136
Metadata
- Authors
- Bataller, R., & Brenner, D. A.
- Affiliations
- Columbia University (US)
- Corresponding author
- Brenner, David A.
- ORCID
- Brenner, David A.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-02-01
- Volume
- 115
- Issue
- 2
- Pages
- 209-218
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4255712601
- Cited by
- 4,958
- References
- 134
- Citations by year
- 2026: 177 · 2025: 236 · 2024: 285 · 2023: 289 · 2022: 307 · 2021: 321 · 2020: 294 · 2019: 275 · 2018: 284 · 2017: 295 · 2016: 281 · 2015: 307 · 2014: 229 · 2013: 224 · 2012: 222
- FWCI
- 17.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministerio de Ciencia y Tecnología
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- liver fibrosis, extracellular matrix accumulation, collagen deposition, chronic liver disease, liver cirrhosis, hepatic stellate cells, portal fibroblasts, myofibroblasts, TGF-β1, angiotensin II, leptin, fibrogenic cytokines, antifibrotic agents, fibrosis pathogenesis, fibrosis diagnosis, liver transplantation
- MeSH terms
- Angiotensin II, Animals, Humans, Hypertension, Portal, Liver Cirrhosis, Transforming Growth Factor beta, Liver Failure, Leptin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
